On Tuesday, Acadia Pharmaceuticals Inc (NASDAQ: ACAD) opened higher 0.47% from the last session, before settling in for the closing price of $17.20. Price fluctuations for ACAD have ranged from $14.15 to $20.68 over the past 52 weeks.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Over the past five-year period, the growth rate of yearbook sales for the company of the Healthcare sector was 23.80%. Company’s average yearly earnings per share was noted -59.88% at the time writing. With a float of $165.50 million, this company’s outstanding shares have now reached $166.71 million.
Considering the fact that the conglomerate employs 654 people, you should pay attention to its efficiency factor. In terms of profitability, gross margin is 91.46%, operating margin of 24.1%, and the pretax margin is 26.94%.
Acadia Pharmaceuticals Inc (ACAD) Breakdown of a Key Holders of the stock
A key investor’s attitude towards the stock of the Biotechnology industry is another important factor to consider. The insider ownership of Acadia Pharmaceuticals Inc is 0.77%, while institutional ownership is 98.28%. The most recent insider transaction that took place on Mar 05 ’25, was worth 89,673. In this transaction Director of this company sold 4,919 shares at a rate of $18.23, taking the stock ownership to the 17,595 shares. Before that another transaction happened on Mar 05 ’25, when Company’s Director proposed sale 4,919 for $18.23, making the entire transaction worth $89,673.
Acadia Pharmaceuticals Inc (ACAD) Recent Fiscal highlights
Wall Street market experts anticipate that the next fiscal year will bring earnings of 0.17 per share during the current fiscal year.
According to the Wall Street analysts, stocks earnings will be around -59.88% per share during the next fiscal year.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Trading Performance Indicators
Check out the current performance indicators for Acadia Pharmaceuticals Inc (ACAD). In the past quarter, the stock posted a quick ratio of 2.32. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 3.01. Likewise, its price to free cash flow for the trailing twelve months is 18.33.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.36, a number that is poised to hit -0.02 in the next quarter and is forecasted to reach 0.93 in one year’s time.
Technical Analysis of Acadia Pharmaceuticals Inc (ACAD)
Compared to the last year’s volume of 2.51 million, its volume of 1.57 million showed lagged in the last five days. As of the previous 9 days, the stock’s Stochastic %D was 40.87%. Additionally, its Average True Range was 0.72.
During the past 100 days, Acadia Pharmaceuticals Inc’s (ACAD) raw stochastic average was set at 47.93%, which indicates a significant increase from 17.12% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 41.46% in the past 14 days, which was lower than the 45.47% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $18.36, while its 200-day Moving Average is $16.79. Nevertheless, the first resistance level for the watch stands at $17.56 in the near term. At $17.84, the stock is likely to face the second major resistance level. The third major resistance level sits at $18.22. If the price goes on to break the first support level at $16.89, it is likely to go to the next support level at $16.51. Now, if the price goes above the second support level, the third support stands at $16.23.
Acadia Pharmaceuticals Inc (NASDAQ: ACAD) Key Stats
There are currently 166,789K shares outstanding in the company with a market cap of 2.88 billion. Presently, the company’s annual sales total 957,800 K according to its annual income of 226,450 K. Last quarter, the company’s sales amounted to 259,600 K and its income totaled 143,740 K.
